Deborah R. Kaye
YOU?
Author Swipe
View article: Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States Open
In this real-world study of patients with disease progression from mCSPC to mCRPC in US clinical practice, nearly 2-in-3 patients did not receive treatment with additional systemic therapies before progression to castration resistance. Pos…
View article: Reply to Editorial Comment: Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study
Reply to Editorial Comment: Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study Open
We appreciate the kind comments of Strup and Harris on our qualitative study.1,2 We agree that there is a significant discrepancy between the clinical aspects of decision making for patients with prostate cancer and the realities of a comp…
View article: Work Absence and Productivity Loss of Patients Undergoing a Trial of Spontaneous Passage for Ureteral Stones
Work Absence and Productivity Loss of Patients Undergoing a Trial of Spontaneous Passage for Ureteral Stones Open
Introduction Patients with ureteral stones are often managed with a spontaneous trial of passage. While cost effective, the current literature has not examined the effects of a trial of passage on patients’ work productivity. In this study…
View article: Reply to Editorial Comment: Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study
Reply to Editorial Comment: Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study Open
We appreciate the kind comments by Dr. Obiora and Dr. Jacobs on our article examining nonclinical factors that affect physician decision-making for patients with advanced prostate cancer. Patient factors, such as race, geographic distribut…
View article: Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study
Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study Open
Introduction: Promising new treatments exist for advanced prostate cancer. Decision-making is complicated: there are minimal comparative effectiveness data; differing routes of administration, drug mechanisms of action, and side effects; a…
View article: Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination
Perspectives on Neoadjuvant Clinical Trial Participation for Patients with Kidney Cancer: A Survey-Based Examination Open
Background: Kidney cancer is amongst the deadliest genitourinary malignancies. Neoadjuvant systemic therapy has the potential to improve survival and overall outcomes in select patients. Enrolling patients in trials of neoadjuvant treatmen…
View article: Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States Open
This real-world study demonstrated a significant economic burden in mCSPC patients, and a propensity to use ADT monotherapy in clinical practice despite the availability and guideline recommendations of advanced life-prolonging therapies.
View article: End-of-Life Care for Patients with Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy
End-of-Life Care for Patients with Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy Open
PURPOSE:New therapies including oral anticancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). However, little is known about the quality of end-of-life (EOL) care and systemic therapy use at…
View article: Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation Open
Incremental costs of progression to mCRPC are significant, with the majority of costs driven by higher PC-related costs. Using contemporary data, this study highlights the importance of utilizing effective therapies that slow progression a…
View article: Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC)
Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC) Open
Objective: To examine real-world adherence to oral anticancer agents (OAAs) and its association with outcomes among Medicare beneficiaries with metastatic renal cell carcinoma (mRCC). Methods: SEER-Medicare retrospective cohort study of pa…
View article: Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients with Metastatic Renal Cell Carcinoma
Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients with Metastatic Renal Cell Carcinoma Open
PURPOSE Availability of targeted oral anticancer agents (OAAs) has transformed care for patients with metastatic renal cell carcinoma (mRCC). Our objective was to identify patterns and predictors of OAA use within 12 months after mRCC was …
View article: Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma Open
Background: Improving oral anticancer agent (OAA) initiation and adherence is the important quality-of-care issues, particularly since one fourth of anticancer agents being developed will be administered orally. Our objective was to identi…
View article: Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States
Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States Open
BACKGROUND: Substantial racial and socioeconomic disparities in metastatic RCC (mRCC) have persisted following the introduction of targeted oral anticancer agents (OAAs). The relationship between patient characteristics and OAA access and …
View article: Drug costs: acquisition costs are critical but not the entire story of financial toxicity
Drug costs: acquisition costs are critical but not the entire story of financial toxicity Open
Benjamin et al. used acquisition and pricing data to determine treatment costs for newly approved second- and third-line agents for metastatic urothelial carcinoma (mUC) [1]. They found that patients who underwent the median duration of tr…
View article: NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023
NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023 Open
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on the pros and cons. These NCC…
View article: Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer Open
PURPOSE: The implications of high prices for cancer drugs on health care costs and patients' financial burdens are a growing concern. Patients with metastatic castrate-resistant prostate cancer (mCRPC) are often candidates for multiple fir…
View article: End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy Open
PURPOSE: New therapies including oral anticancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). However, little is known about the quality of end-of-life (EOL) care and systemic therapy use a…
View article: Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC)
Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC) Open
View article: Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma
Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma Open
Background Kidney cancer is the fastest‐growing cancer diagnosis in the developed world. About 16% of new cases are stage IV, which has a low five‐year survival rate. Many patients with metastatic renal cell carcinoma (mRCC) are older and …
View article: Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents
Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents Open
View article: Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma
Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma Open
View article: Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma
Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma Open
View article: Risk factors for dementia onset in older adults with metastatic renal cell carcinoma
Risk factors for dementia onset in older adults with metastatic renal cell carcinoma Open
Renal dysfunction is a driver of dementia. It is also associated with renal cell carcinoma, possibly the result of the tumor itself or from cancer treatment. This study evaluates metastatic renal cell carcinoma (mRCC) as a risk factor for …
View article: Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma
Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma Open
Background Improving oral anticancer agent (OAA) initiation and adherence is the important quality‐of‐care issues, particularly since one fourth of anticancer agents being developed will be administered orally. Our objective was to identif…
View article: Ischemic priapism due to coagulopathy of severe COVID-19 infection
Ischemic priapism due to coagulopathy of severe COVID-19 infection Open
Initially thought to be a primarily respiratory disease process, the hypercoagulable state associated with COVID-19 has been associated with myriad clinical sequelae. We report a case of stuttering ischemic priapism associated with COVID-1…
View article: Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States
Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States Open
BACKGROUND: Substantial racial and socioeconomic disparities in metastatic RCC (mRCC) have persisted following the introduction of targeted oral anticancer agents (OAAs). The relationship between patient characteristics and OAA access and …
View article: Association Between Delivery System Structure and Intensity of End-of-Life Cancer Care
Association Between Delivery System Structure and Intensity of End-of-Life Cancer Care Open
PURPOSE: To determine whether the type of delivery system is associated with intensity of care at the end of life for Medicare beneficiaries with cancer. PATIENTS AND METHODS: We used SEER registry data linked with Medicare claims to evalu…
View article: MP44-08 QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE FOR DUAL ELIGIBLE BENEFICIARIES AND THE IMPACT OF DELIVERY SYSTEM INTEGRATION
MP44-08 QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE FOR DUAL ELIGIBLE BENEFICIARIES AND THE IMPACT OF DELIVERY SYSTEM INTEGRATION Open
You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Practice Patterns, Quality of Life and Shared Decision Making III (MP44)1 Apr 2019MP44-08 QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE FOR DUAL ELI…
View article: PD52-07 THE FEASIBILITY, SAFETY AND IMPACT OF A PREHABILITATION PROGRAM FOR PATIENTS UNDERGOING CYSTECTOMY
PD52-07 THE FEASIBILITY, SAFETY AND IMPACT OF A PREHABILITATION PROGRAM FOR PATIENTS UNDERGOING CYSTECTOMY Open
You have accessJournal of UrologyBladder Cancer: Invasive V (PD52)1 Apr 2019PD52-07 THE FEASIBILITY, SAFETY AND IMPACT OF A PREHABILITATION PROGRAM FOR PATIENTS UNDERGOING CYSTECTOMY Deborah R. Kaye*, Steven Thelen-Perry, Christine Schafer…
View article: PD58-07 HEALTH SYSTEM CHARACTERISTICS AND THE QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE
PD58-07 HEALTH SYSTEM CHARACTERISTICS AND THE QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE Open
You have accessJournal of UrologyGeneral & Epidemiological Trends & Socioeconomics: Quality Improvement & Patient Safety IV (PD58)1 Apr 2019PD58-07 HEALTH SYSTEM CHARACTERISTICS AND THE QUALITY OF UROLOGICAL CANCER CARE AT THE END OF LIFE …